Philip E. Thorpe

Q: What Schools Are Affiliated With Philip E. Thorpe

Philip E. Thorpe is affiliated with the following schools: University of Washington, University of Texas Southwestern Medical Center

Philip E. Thorpe's AcademicInfluence.com Rankings

Philip E. Thorpe

Philosophy

#9221

World Rank

#12750

Historical Rank

Logic

#6208

World Rank

#7700

Historical Rank

philosophy Degrees

Philip E. Thorpe

Biology

#12646

World Rank

#16137

Historical Rank

Biochemistry

#2174

World Rank

#2319

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Philip E. Thorpe's Degrees

PhD Biochemistry University of Texas Southwestern Medical Center
Doctorate Medicine University of Texas Southwestern Medical Center

Why Is Philip E. Thorpe Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Philip E. Thorpe's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (2000) (2727)
Vascular Targeting Agents as Cancer Therapeutics (2004) (563)
Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature (1997) (500)
Increased exposure of anionic phospholipids on the surface of tumor blood vessels. (2002) (448)
Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. (1995) (350)
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. (2000) (340)
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo (2002) (337)
The Preparation and Cytotoxic Properties of Antibody‐Toxin Conjugates (1982) (253)
Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. (2002) (246)
Immunotoxins: magic bullets or misguided missiles? (1993) (224)
New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. (1987) (223)
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. (2004) (212)
Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. (1993) (209)
Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. (2004) (193)
Targeting Inside-Out Phosphatidylserine as a Therapeutic Strategy For Viral Diseases (2008) (191)
Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. (2011) (183)
Vascular endothelial growth factor as a marker of tumor endothelium. (1998) (178)
Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies (2004) (167)
Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. (1988) (162)
The first international conference on vascular targeting: meeting overview. (2003) (159)
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. (2000) (145)
Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. (1987) (143)
Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice (2005) (142)
Increased exposure of phosphatidylethanolamine on the surface of tumor vascular endothelium. (2011) (141)
Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. (1998) (141)
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors (2002) (140)
An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. (1985) (139)
Vascular targeting--a new approach to the therapy of solid tumors. (1994) (139)
A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. (2005) (136)
Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. (1985) (125)
Ultrastructural Localization of the Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Receptor-2 (FLK-1, KDR) in Normal Mouse Kidney and in the Hyperpermeable Vessels Induced by VPF/VEGF-expressing Tumors and Adenoviral Vectors (2000) (118)
Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation (2013) (117)
Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin. (1981) (114)
Antiphosphatidylserine Antibody Combined with Irradiation Damages Tumor Blood Vessels and Induces Tumor Immunity in a Rat Model of Glioblastoma (2009) (113)
A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model (2004) (110)
The angiogenic pathway ‘vascular endothelial growth factor/flk‐1(KDR)‐receptor’ in rheumatoid arthritis and osteoarthritis (2001) (105)
Selective killing of malignant cells in a leukaemic rat bone marrow using an antibody–ricin conjugate (1982) (101)
Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. (2001) (98)
Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. (1990) (98)
Purification of ricin A1, A2, and B chains and characterization of their toxicity. (1986) (95)
Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed Phosphatidylserine (2008) (93)
Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids (2007) (91)
Blockade of the galactose-binding sites of ricin by its linkage to antibody. Specific cytotoxic effects of the conjugates. (1984) (88)
Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. (1988) (87)
Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro. (1991) (87)
Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. (1990) (86)
Evaluation of four CD22 antibodies as ricin a chain‐containing immunotoxins for the in vivo therapy of human B‐cell leukemias and lymphomas (1988) (83)
The angiogenic “vascular endothelial growth factor/flk‐1(KDR) receptor” pathway in patients with endometrial carcinoma (2001) (82)
Expression of ricin A chain in Escherichia coli (1987) (82)
Vascular endothelial growth factor and vascular targeting of solid tumors. (2001) (81)
Effect of Rapamycin Alone and in Combination with Antiangiogenesis Therapy in an Orthotopic Model of Human Pancreatic Cancer (2004) (80)
Purification of immunotoxins containing ricin A-chain and abrin A-chain using blue sepharose CL-6B. (1987) (79)
A novel "salting-out" procedure for the isolation of tumor-derived exosomes. (2014) (78)
Antibody toxin conjugates: a perspective. (1988) (74)
[16] Preparation of antibody—toxin conjugates (1985) (74)
Immunotoxins containing ricin or its A chain. (1991) (74)
The removal of carbohydrates from ricin with endoglycosidases H, F and D and α-mannosidase (1985) (72)
Optimal conditions for the preservation of mouse lymph node cells in liquid nitrogen using cooling rate techniques. (1976) (72)
Antibody-directed targeting of the vasculature of solid tumors (2004) (72)
Combination of a monoclonal anti‐phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice (2006) (69)
Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocytic globulin (1978) (68)
Plasma Protein β-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells* (2006) (66)
Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors (2011) (65)
Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice. (2014) (63)
Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. (1993) (61)
A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. (1992) (61)
Multimodality imaging of hypoxia in preclinical settings. (2010) (61)
Anti‐tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate‐specific membrane antigen (2004) (59)
Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells. (2008) (59)
Microplate culture of mouse lymph node cells. I. Quantitation of responses to allogeneic lymphocytes endotoxin and phytomitogens. (1974) (56)
Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β-chemokines (2010) (55)
Immunotoxins constructed with anti‐CD25 monoclonal antibodies and deglycosylated ricin a‐chain have potent anti‐tumour effects against human hodgkin cells in vitro and solid hodgkin tumours in mice (1991) (54)
The use of anti-ricin antibodies to protect mice intoxicated with ricin. (1985) (52)
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. (2000) (52)
In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11 (1997) (50)
The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. (1991) (49)
VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. (2001) (49)
Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. (2003) (49)
An immunotoxin with therapeutic potential in T cell leukemia: WT1-ricin A (1984) (48)
Effect of chemical deglycosylation on the in vivo fate of ricin A-chain. (1986) (48)
Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants. (1987) (48)
Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. (2011) (47)
Cytotoxicity of a recombinant ricin‐A‐chain fusion protein containing a proteolytically‐cleavable spacer sequence (1990) (47)
Organ‐specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene‐targeting of the PI3K regulatory isoforms p85α, p55α, and p50α (2009) (45)
Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells. (2003) (43)
A new method for radiochemical separation of arsenic from irradiated germanium oxide. (2005) (43)
An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins. (1988) (41)
Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo. (1988) (40)
Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin (1987) (40)
Exogenous BH4/Bcl-2 Peptide Reverts Coronary Endothelial Cell Apoptosis Induced by Oxidative Stress (2004) (40)
Neuronotoxic effects of monoclonal anti-Thy 1 antibody (OX7) coupled to the ribosome inactivating protein, saporin, as studied by suicide transport experiments in the rat (1989) (39)
The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. (1989) (38)
The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. (2005) (37)
Increased toxicity of diphtheria toxin for human lymphoblastoid cells following covalent linkage to anti-(human lymphocyte) globulin or its F(ab')2 fragment. (1980) (36)
Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells. (1988) (36)
Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. (1998) (36)
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. (2005) (36)
Hepatotoxicity of immunotoxins made with saporin, a ribosome-inactivating protein fromSaponaria officinalis (1987) (36)
Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins (1994) (34)
An Orthotopic Lung Tumor Model for Image-Guided Microirradiation in Rats (2010) (34)
Modification of the carbohydrate in ricin with metaperiodate and cyanoborohydride mixtures: effect on binding, uptake and toxicity to parenchymal and non-parenchymal cells of rat liver. (1985) (33)
Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. (2006) (33)
Near-infrared Optical Imaging of Exposed Phosphatidylserine in a Mouse Glioma Model. (2011) (31)
Quantitative assessment of tumor oxygen dynamics: Molecular imaging for prognostic radiology (2002) (31)
A new method for the labelling of proteins with radioactive arsenic isotopes (2006) (30)
Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin. (1981) (29)
Cocktails of ricin a‐chain immunotoxins against different antigens on hodgkin and sternberg‐reed cells have superior anti‐tumor effects against H‐RS cells in vitro and solid Hodgkin tumors in mice (1995) (29)
Tumor infarction by targeting tissue factor to tumor vasculature. (2000) (29)
Preparation of antibody-toxin conjugates. (1985) (29)
Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. (2011) (28)
Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors (2010) (27)
AN IMMUNOTOXIN OF RICIN A CHAIN CONJUGATED TO THYROGLOBULIN SELECTIVELY SUPPRESSES THE ANTI-THYROGLOBULIN AUTOANTIBODY RESPONSE (1983) (26)
COADMINISTRATION OF LOW‐DOSE LIPOPOLYSACCHARIDE AND SOLUBLE TISSUE FACTOR INDUCES THROMBOSIS AFTER RADIOSURGERY IN AN ANIMAL ARTERIOVENOUS MALFORMATION MODEL (2007) (26)
Targeting anionic phospholipids on tumor blood vessels and tumor cells. (2010) (26)
Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti‐T cell immunotoxins (1987) (25)
Highly Specific PET Imaging of Prostate Tumors in Mice with an Iodine-124-Labeled Antibody Fragment That Targets Phosphatidylserine (2013) (25)
Semaphorin 3 B ( SEMA 3 B ) induces apoptosis in lung and breast cancer , whereas VEGF 165 antagonizes this effect (2004) (25)
Prevention of ischemic brain injury by treatment with the membrane penetrating apoptosis inhibitor, TAT-BH4 (2009) (25)
Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery. (2012) (24)
Phosphatidylserine exposure on the surface of Leishmania amazonensis amastigotes modulates in vivo infection and dendritic cell function (2013) (22)
The preparation of deglycosylated ricin by recombination of glycosidase-treated A- and B-chains: effects of deglycosylation on toxicity and in vivo distribution. (1987) (22)
Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis (2016) (22)
Characterization of the cell‐surface procoagulant activity of T‐lymphoblastoid cell lines (2004) (21)
Targeting the vasculature of solid tumors (1993) (21)
Phosphatidylserine-targeted molecular imaging of tumor vasculature by magnetic resonance imaging. (2014) (21)
Phosphatidylserine externalization and membrane blebbing are involved in the nonclassical export of FGF1 (2012) (21)
Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts (2016) (20)
Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins. (1991) (20)
An immunotoxin with therapeutic potential in T cell leukemia: WT1-ricin A. (1984) (20)
Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines. (2001) (18)
Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method for labelling antibodies with 32P. (1988) (18)
Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts. (2015) (18)
Retargeting Adenoviral Vectors to Improve Gene Transfer into Tumors (2010) (17)
Selective killing of contaminating human fibroblasts in epithelial cultures derived from colorectal tumours using an anti Thy-1 antibody-ricin conjugate. (1985) (16)
Prevention of carbohydrate-mediated clearance of ricin-containing immunotoxins by the liver. (1988) (16)
Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin. (1988) (15)
Ricin B chain-containing immunotoxins prepared with heat-denatured B chain lacking galactose-binding ability potentiate the cytotoxicity of a cell-reactive ricin A chain immunotoxin. (1988) (15)
Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins. (1994) (15)
Antibody Toxin Conjugates: A Perspective (Part 1 of 2) (1988) (15)
Heparin-steroid conjugates lacking glucocorticoid or mineralocorticoid activities inhibit the proliferation of vascular endothelial cells. (1996) (14)
Granulocyte-Colony Stimulating Factor Receptor, Tissue Factor, and VEGF-R Bound VEGF in Human Breast Cancer In Loco. (2016) (14)
Cytotoxicity of VEGF121/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2 (2011) (14)
Immunotoxins containing ricin A or B chains with modified carbohydrate residues act synergistically in killing neoplastic B cells in vitro. (1985) (14)
Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin (2005) (13)
A comparison of the in vitro and in vivo activities of conjugates of anti-mouse lymphocyte globulin and abrin. (1982) (12)
Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. (1994) (12)
Erratum: In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors (Proceedings of the National Academy of Sciences of the United States of America (June 11, 2002) 99:12 (7866-7871)) (2002) (12)
TAT-BH4 counteracts Abeta toxicity on capillary endothelium. (2007) (11)
Circular dichroism of isolated ricin A- and B-chains. (1988) (11)
Targeting toxins — the retiarian approach to chemotherapy (1981) (11)
Anti‐tumor and anti‐angiogenic effects in mice of heparin conjugated to angiostatic steroids (1995) (11)
Elimination of leukaemic cells from rodent bone marrow in vitro with antibody-ricin conjugates: Implications for autologous marrow transplantation in man (1982) (10)
The removal of carbohydrates from ricin with endoglycosidases H, F and D and alpha-mannosidase. (1985) (9)
UTSW Small Animal Positron Emission Imager (2006) (9)
Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas (2004) (9)
Effect of chemical linkage upon the stability and cytotoxic activity of A chain immunotoxins. (1988) (8)
Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. (2011) (7)
Strategies for labeling proteins with PARACEST agents. (2011) (6)
Enzymic removal of two oligosaccharide chains from ricin B‐chain (1986) (6)
Oxygenation in a human tumor xenograft: manipulation through respiratory challenge and antibody-directed infarction. (2003) (6)
Coexpression of MUC 1 Glycoprotein with Multiple Angiogenic Factors in Non-Small Cell Lung Cancer Suggests Coactivation of Angiogenic and Migration Pathways 1 (2000) (5)
Immunotoxins: magic bullets or misguided missiles? (1993) (5)
Treatment of malignant disease and rheumatoid arthritis using ricin A-chain immunotoxins. (1988) (5)
Protective Effect of Anti-Phosphatidylserine Antibody in a Guinea Pig Model of Advanced Hemorrhagic Arenavirus Infection (2017) (4)
Monoclonal antibody therapy: "model" experiments with toxin-conjugated antibodies in mice and rats. (1983) (4)
A simple and rapid method for purifying the extracellular domain of human tissue factor. (1998) (4)
Role of the B-Chain in the Cytotoxic Action of Antibody-Ricin and Antibody-Abrin Conjugates (1984) (4)
Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. (2012) (4)
A novel membrane-acting immunotoxin, the immunolysin, with therapeutic potential. (1992) (3)
Abstracts of papers and posters (2005) (3)
Cryopreservation of mouse lymphocytes (1974) (3)
Potent antitumor effects of an antitumor endothelial cell immunotoxin in a murine vascular targeting model (2007) (3)
Abstract #5463: Fully human anti-phosphatidylserine antibody inhibits the growth of prostate cancer in mice (2009) (2)
The Potential of Membrane-Acting Toxins for Targeted Cancer Therapy (1988) (2)
Antibody-ricin conjugates: a method of linkage which blocks the galactose binding site of ricin. (1984) (2)
What's new: Immunotoxins (1986) (2)
Abstract 4395: Cure of castration-resistant prostate cancer in TRAMP mice by reactivating tumor immunity with a phosphatidylserine-targeting antibody (2012) (2)
Selected Antibodies and Duramycin Peptides that bind to anionic phospholipids and aminophospholipids and their uses in the treatment of viral infections and cancer. (2003) (2)
Identification of a tyrosine residue in the saccharide binding site of ricin B‐chain using N‐[14C]acetylimidazole (1987) (2)
Abstract 621: Targeting phosphatidylserine to improve androgen deprivation therapy of prostate cancer (2011) (2)
Phosphatidylserine-targeting antibody induces M1 macrophage polarization, promotes myeloid derived suppressor cell differentiation and boosts tumor-specific immunity (2013) (1)
Anti‐viral Effects of Phosphatidylethanolamine‐targeting agents (2008) (1)
[New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?]. (1992) (1)
IBC’s 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society (2012) (1)
Abstract 4632: Phosphatidylserine-targeting ‘betabodies’ for the treatment of cancer (2012) (1)
Antibody-Toxin Conjugates as Anti-Cancer Agents (1984) (1)
Vascular Endothelial Growth Factor Isoforms Display Distinct Activities in Promoting Tumor Angiogenesis at Different Anatomic Sites 1 (2001) (1)
Targeting Inside‐Out Phospholipids on Tumor Blood Vessels in Pancreatic Cancer (2006) (1)
Abstract 3643: Phosphatidylserine-targeting antibody combined with Sorafenib has strong anti-tumor activity against human hepatocellular carcinomas in mice (2011) (1)
Targeting of Anionic Phospholipids Exposed on Infected Cells and Virions: Potential Broad-Spectrum Antiviral Therapy (2010) (1)
ANTIBODY-MEDIATED TARGETING OF “INSIDE-OUT” ANIONIC PHOSPHOLIPIDS IN VIRAL DISEASE (47.21) (2007) (1)
/ rGel 121 by the Vascular Targeting Agent VEGF Inhibition of Prostate Tumor Growth and Bone Remodeling (2006) (1)
Antibody-Toxin Conjugates as Potential Therapeutic Agents (1982) (1)
The Development of Ricin A-Chain Immunotoxins for Clinical Trials in Patients with Hodgkin’s Disease (1992) (1)
[Immunotoxin: from the idea of "magic bullets" to clinical applications]. (1990) (1)
New strategies for therapy of breast cancer (2004) (0)
Antiphospholipid Antibodies Promote Leukocyte-Endothelial Cell Adhesion by Antagonizing Endothelial NO Synthase Via b2GPI and ApoER2. (2009) (0)
Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium1 (2006) (0)
Antibody Targeting of Tumor Vasculature (2002) (0)
The development of immunotoxins for the treatment of B-cell lymphoma (1993) (0)
Anti-phosphatidylserine Antibodies As A Potential New Therapy Against Choroidal Neovascularization (2012) (0)
Chimeric proteins containing ricin A chain. (1992) (0)
Use of anti-aminophospholipid antibodies for cancer treatment (1999) (0)
Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium 1 (2006) (0)
The Effect of Chemical Deglycosylation of Ricin A-Chain on the Therapeutic Potential of Ricin A-Chain Immunotoxins (1988) (0)
Abstract 5330: Phosphatidylserine-targeting antibody enhances survival benefit of androgen deprivation therapy in mice bearing syngeneic prostate cancer (2010) (0)
Method for treating cancer using antibodies aminofosfolipìdios (1999) (0)
Screening of 19 Monoclonal Antibodies for their Potential as Ricin A-Chain Immunotoxins Against Myeloid Leukemia Cell Lines (1992) (0)
Targeting Toxins by Conjugation to Antibodies: The Effect of the Linkage Group on Biological Activity (1984) (0)
Methods of cancer treatment using therapeutic conjugates that bind to aminophospholipids. (1999) (0)
Selected antibodies that bind to aminophospholipids and its use in cancer treatment (2003) (0)
Use of immunoconjugates for diagnosis and / or treatment of vascularized tumors (1993) (0)
Abstract 3651: Phosphatidylserine-targeting antibody induces differentiation of myeloid-derived suppressor cells into M1-like macrophages (2011) (0)
Selected antibodies that bind to aminophospholipids and their use in therapy such as cancer (2003) (0)
Anti-tumor Effects of Monoclonal Antibody-ricin Conjugates In Vitro and In Vivo (1988) (0)
Overcoming cisplatin-resistance of breast cancer in mice by co-administering cisplatin and anti-phosphatidylserine antibody, 3G4 (2006) (0)
Antibody-ricin conjugates (1984) (0)
Use of immunoconjugates for diagnosis and / or therapy of tumors vascularizaos. (1993) (0)
Expression of Vascular Endothelial Growth Factor (VEGF) Associated with Its Receptor (VEGFR) in Relation to Tissue Factor (TF) in Human Breast Cancer Tissue. (2005) (0)
Methods and compositions of tissue factor to coagulation and treatment of tumors (1998) (0)
Compositions and methods for the treatment of cancer through inhibition selective of vegf. (2000) (0)
Erratum: Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocyte globulin (Nature (1978) 271, (752)) (1978) (0)
Vasculature Antibody-directed Targeting of Tissue Factor to Tumor Infarction of Solid Hodgkin ' s Tumors in Mice by Updated Version (2006) (0)
Antibodies that bind to anionic phospholipids and aminophospholipids, and their use for the treatment of viral infections (2003) (0)
Immunotoxins against the vasculature of human Hodgkin’s lymphoma in SCID mice (2007) (0)
Reply to the letter of Griffioen et al. on endoglin/CD 105 as a tumor endothelial treatment target (1996) (0)
Selective killing of malignant cells fey antibody-ricin conjugates (‘immunotoxins’) (1990) (0)
Compositions and methods of cancer treatment by the selective inhibition of VEGF (2000) (0)
Fusion proteins composed of mouse IgG2a Fc and mouse beta-2-glycoprotein 1 bind to endothelial cells with exposed phosphatidylserine (2007) (0)
Abstract 5232: Phosphatidylethanolamine is a marker of tumor vasculature and can be used as a target for optical imaging (2010) (0)
Antitumor Effects of Six Ricin A-Chain Immunotoxins of Potential Use in the Treatment of Hodgkin’S Disease (1990) (0)
Abstract 1244: Phosphatidylserine-targeting antibody reactivates tumor immunity and destroys tumor vasculature in mice. (2013) (0)
Monoclonal antibodies as pharmacological agents: Comparison of the antitumour effects of two anti-thy 1.1 abrin a conjugates prepared with different coupling agents (1985) (0)
Anti-phosphatidylserine monoclonal antibody, 3G4, enhances the anti-tumor effects of docetaxel against human breast cancer (2004) (0)
Selective direction of ricin to hepatic parenchymal cells (1982) (0)
The effect of abrin, anti-lymphocyte globulin and their conjugates on the immune response of mice to sheep red blood cells (1981) (0)
On the immune response of mice to sheep red blood cells. (1981) (0)
Antibodies binding to anionic phospholipides and aminophospholipides and their use in the treatment of virus infections (2003) (0)
An Anti-Phosphatidylserine (PS) Antibody, Tarvacin™ That Targets Tumor Blood Vessels Does Not Affect Platelet Function In Vitro. (2005) (0)
Anatomic Sites Activities in Promoting Tumor Angiogenesis at Different Vascular Endothelial Growth Factor Isoforms Display Distinct Updated (2001) (0)
Antibody Toxin Conjugates: A Perspective (Part 2 of 2) (1988) (0)
Angiopoietin-2 transfection does not enhance the sensitivity of the NCI-H358 lung tumor to VEGF-neutralizing therapy (2002) (0)
Contents of Volume 5 (2002) (2004) (0)
Image quantification of sentinel node uptake using 99Tcm-Nanocoll in 14 patients (1999) (0)
In vitro treatment of bone marrow from patients with T-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma using the immunotoxin WT1-ricin A. (1987) (0)
Ligand-Directed Destruction of Tumor Vasculature (2002) (0)
of Tumor Blood Vessels Increased Exposure of Anionic Phospholipids on the Surface Updated (2002) (0)
Abstract 1919: Phosphatidylserine on dying tumor cells suppresses dendritic cell activation and inhibits tumor immunity: reversal with PS-targeting antibody (2010) (0)
Immunotargeting of tumor vessels for cancer therapy (1997) (0)
Inhibition of pancreatic tumor growth and metastasis in mice by targeting inside-out phospholipids on tumor vasculature (2005) (0)
Methods and compositions for specific coagulation of tumor vasculature (1995) (0)
Antibody toxin conjugates (1988) (0)
The First International Conference on Vascular Targeting : Meeting Overview 1 (2003) (0)
Combined targeting of exposed phosphatidylserine, CD47 and CD54 on human pancreatic tumor cells in a mouse xenograft model of human pancreatic cancer (P4455) (2013) (0)
Following are the abstracts from the Fourth Annual Meeting of the Society for Molecular Imaging (2005) (0)
In vivo imaging of tumor vascular endothelial cells (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Philip E. Thorpe?

Philip E. Thorpe is affiliated with the following schools:

Philip E. Thorpe's Academic­Influence.com Rankings

Philip E. Thorpe's Degrees

Why Is Philip E. Thorpe Influential?

Philip E. Thorpe's Published Works

Published Works

What Schools Are Affiliated With Philip E. Thorpe?

Philip E. Thorpe's AcademicInfluence.com Rankings